HBS
TEVA icon

Howard Bailey Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Howard Bailey Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,523
Closed -$297K – 151
2025
Q4 		$297K Sell
9,523
-6,058
-39% -$149K 0.12% 104
2025
Q3 		$315K Buy
15,581
+510
+3% +$8.96K 0.09% 106
2025
Q2 		$253K Sell
15,071
-7,378
-33% -$119K 0.08% 126
2025
Q1 		$345K Buy
22,449
+102
+0.5% +$1.82K 0.12% 100
2024
Q4 		$493K Buy
22,347
+101
+0.5% +$1.84K 0.18% 74
2024
Q3 		$401K Buy
+22,246
New +$389K 0.15% 94

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Howard Bailey Securities's TEVA Position: Q1 2026 in Review

Howard Bailey Securities sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 9,523 shares — an estimated $297K sold.

Howard Bailey Securities first reported a position in TEVA in Q3 2024 and held it in 6 quarters. The position peaked at $493K in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Howard Bailey Securities reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Howard Bailey Securities sold 9,523 Teva Pharmaceuticals shares in Q1 2026, an estimated $297K.
  • Howard Bailey Securities first reported a position in Teva Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Howard Bailey Securities's Teva Pharmaceuticals position peaked at $493K in Q4 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Howard Bailey Securities's 13F filing for Q1 2026, filed 23 Apr 2026.